Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol
Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions
using a single-dose, randomized, 2-treatment, 2-period, crossover design.